FRANKFURT, Deutschland, 15. September 2024 /PRNewswire/ -- Die China Petroleum & Chemical Corporation (Sinopec, HKG: 0386) wurde auf der ersten Sino-European Corporate ESG Best Practice Conference in Frankfurt mit dem Best Environmental Protection Case Award (Preis für den besten Beitrag zum Umweltschutz) ausgezeichnet. Die Veranstaltung fand im Kongresszentrum der Messe Frankfurt statt und würdigte die herausragenden Beiträge von Sinopec zur nachhaltigen Entwicklung.

Unter dem Motto Together for the Future wurden auf der Konferenz die besten Fälle in zehn Kategorien vorgestellt, darunter Umweltschutz, soziale Verantwortung, Unternehmensführung und technologische Innovation. Ziel war es, den Dialog und die Zusammenarbeit zwischen chinesischen und europäischen Unternehmen im Bereich der nachhaltigen Entwicklung zu fördern und das Verständnis für Chinas Fortschritte in der deutschen und europäischen Industrie zu vertiefen.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. ("Acadia Healthcare" or "the Company") (NASDAQ: ACHC). Investors who purchased Acadia Healthcare securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACHC.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE: RTO). Investors who purchased Rentokil securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RTO.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE: TARO) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Taro securities pursuant to the registration statement and prospectus issued in connection with the Company's January 25, 2024 initial public offering ("IPO"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/TARO.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Transocean Ltd. ("Transocean" or "the Company") (NYSE: RIG). Investors who purchased Transocean securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RIG.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flux Power Holdings, Inc. ("Flux" or "the Company") (NASDAQ: FLUX). Investors who purchased Flux securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLUX.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Spire Global, Inc. ("Spire" or "the Company") (NYSE: SPIR) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Spire securities between March 6, 2024, and August 14, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/SPIR.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

NEW YORK-, Sept. 15, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aviat Networks, Inc. ("Aviat" or "the Company") (NASDAQ: AVNW). Investors who purchased Aviat securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AVNW.

The collaboration enables independent advisors to deliver holistic advisory services across the full balance sheet with integrated SBL capabilities to see the borrowing power for portfolios.

NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Global fintech leader Broadridge Financial Solutions, Inc. (NYSE:BR) announces the securities-based lending (SBL) tools in its Wealth Lending Network (WLN) marketplace are now integrated in Morningstar Advisor Workstation. Extending beyond Workstation's core research, investment planning, and portfolio analysis capabilities, independent advisors now have seamless access to lending solutions that help them support broader client financial goals.

RADNOR, Pa. , Sept. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PDD Holdings Inc. f/k/a Pinduoduo Inc. ("PDD") (NASDAQ: PDD) on behalf of investors who purchased or otherwise acquired PDD securities between April 30, 2021 and June 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 15, 2024.

RADNOR, Pa., Sept. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Extreme Networks, Inc. ("Extreme") (NASDAQ: EXTR) on behalf of investors who purchased or otherwise acquired Extreme common stock between July 27, 2022 and January 30, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 15, 2024.

ir@fissionuranium.comwww.fissionuranium.com

TSX SYMBOL: FCUOTCQX SYMBOL: FCUUF FRANKFURT SYMBOL: 2FU

/NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES/

KELOWNA, BC, Sept. 15, 2024 /CNW/ - FISSION URANIUM CORP. (TSX: FCU) (OTCQX: FCUUF) ("Fission" or the "Company") announced today that the hearing for the final order (the "Final Order") approving the previously announced plan of arrangement (the "Arrangement") with Paladin Energy Limited ("Paladin") began before the Supreme Court of British Columbia on September 13, 2024 and will continue on September 26, 2024.

RADNOR, Pa., Sept. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against lululemon athletica inc. ("lululemon") (NASDAQ: LULU) on behalf of investors who purchased or otherwise acquired lululemon securities between December 7, 2023 and July 24, 2024, inclusive (the "Class Period"). The case is assigned to the Honorable Andrew Lamar Carter Jr. The lead plaintiff deadline is October 7, 2024.

Partnership will Accelerate Global Expansion of Virtual Vehicle

Trimble to Become a Shareholder in Platform Science's Expanded Business

WESTMINSTER, Colo. and SAN DIEGO, Sept. 15, 2024 /PRNewswire/ -- Trimble (NASDAQ: TRMB) and Platform Science announced today they are partnering to transform the transportation industry through a definitive agreement for Platform Science to acquire Trimble's global transportation telematics business units. As part of this agreement, Trimble will become a shareholder in Platform Science's expanded business.

HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47 antibody AK117) , in combination with FOLFOXIRI as a first-line (1L) treatment for metastatic colorectal cancer (mCRC). The principal investigator of the study, Professor Yanhong Deng from the Sixth Affiliated Hospital of Sun Yat-Sen University, delivered an oral presentation at the conference.

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated

HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47 antibody AK117) for the first-line treatment of PD-L1-positive (CPS≥1) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

At the data cut-off date of March 19, 2024, results indicate that for HNSCC with a high need for rapid tumor reduction, the ivonescimab regimen has demonstrated clinically meaningful reduction in tumor size. When combined with ligufalimab, both tumor shrinkage and survival benefits demonstrated further improvement from ivonescimab alone. Both ivonescimab alone and the ivonescimab plus ligufalimab combination have achieved preliminary efficacy data that surpassed previously disclosed PD-1 studies.

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive

BARCELONA, Spain, Sept. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). New data were featured in a late-breaking oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress (Abstract #LBA85).

MONTREAL, Sept. 15, 2024 /CNW/ - Air Canada today said it has reached a tentative, four-year collective agreement with the Air Line Pilots Association (ALPA), representing more than 5,200 pilots at Air Canada and Air Canada Rouge.

The new agreement recognizes the contributions and professionalism of Air Canada's pilot group, while providing a framework for the future growth of the airline. Terms of the new agreement will remain confidential pending a ratification vote by the membership, expected to be completed over the next month, and approval by the Air Canada Board of Directors.